Hugh Cole - Jan 7, 2022 Form 4 Insider Report for Jounce Therapeutics, Inc. (JNCE)

Role
Chief Business Officer
Signature
/s/ Caroline Gammill, Attorney-in-fact
Stock symbol
JNCE
Transactions as of
Jan 7, 2022
Transactions value $
-$66,580
Form type
4
Date filed
1/11/2022, 07:55 PM
Previous filing
Jun 2, 2021
Next filing
Mar 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNCE Common Stock Sale -$25.3K -3.47K -4.69% $7.30 70.4K Jan 7, 2022 Direct F1, F2
transaction JNCE Common Stock Sale -$41.3K -6.21K -8.81% $6.65 64.2K Jan 10, 2022 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
F2 Represents the weighted average share price of an aggregate total of 3,468 shares sold in the price range of $7.03 to $7.65 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 6,205 shares sold in the price range of $6.57 to $6.90 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.